Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Targeted Therapy of Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans
Primary: Number of Subjects Who Failed Treatment — 2 Participants
Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Phase 2 N=7 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Bronchiolitis Obliterans · Constructive Bronchiolitis · Graft Versus Host Disease
Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants
Phase 2 N=23 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Constrictive Bronchiolitis · Bronchiolitis Obliterans · Graft vs Host Disease
Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Phase 3 N=62 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (L) From Baseline to Week 48 — -0.186; -0.090 liters — p=0.7310
Phase 4 N=30 Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)
Complication of Transplanted Lung
Primary: Change in Pulmonary Function, as Measured by Serial Forced Expiratory Volume in 1 Second (FEV1) on Spirometry — -0.04 Liter — p=0.2030
Phase 3 N=169 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (Liters) From Baseline to Week 48 — -0.096; -0.067 Liters — p=0.6639
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
Phase 2 N=21 Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
Disorder Related to Lung Transplantation · Bronchiolitis Obliterans · Decreased Immunologic Activity
Primary: Number Of Participants With Chronic Rejection Who Met Primary Combined End-point — 2; 5 Participants — p=0.03
Phase 2 N=16 Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants
Phase 2 N=5 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant
Primary Immunodeficiency · PID
Primary: Safety: Death — 4 Participants
N/A N=50 BPD Saturation TARgeting
Bronchopulmonary Dysplasia · Chronic Lung Disease of Prematurity · Chronic Lung Disease
Primary: Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time — 2.2; 1.2 IH events per 8 hours of monitoring time
N/A N=45 Using Ultrasound Elastography to Predict Development of SOS
Sinusoidal Obstruction Syndrome · Complications of Bone Marrow Transplant
Primary: Sensitivity and Specificity of US for VOD/SOS — 80; 93 percentage of participants
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
N/A N=256 Analysis of BPD in Premature Infants With Typical Imaging Changes
Bronchopulmonary Dysplasia
Primary: Mortality — 17; 7 Participants
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
Phase 2 N=20 Hyperbaric Oxygen Therapy for Lung Transplantation
Disorder Related to Lung Transplantation · Central Airway Stenosis · Airway Exudative Plaques
Primary: Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy. — 4; 4 Participants — p=1
Phase 2 N=61 LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Acute Respiratory Distress Syndrome (ARDS)
Primary: Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2) Ratio — 320; 334; 376; 336 SpO2/FiO2 Ratio — p=0.02
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants
Phase 2 N=45 B Cell Induction in Pediatric Lung Transplantation
Lung Transplant
Primary: Earliest Time to Any of the Following Events: Chronic Allograft Dysfunction, Listed for Retransplant or Death — NA; 703 Days — p=0.514
Phase 2 N=124 Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Bronchopulmonary Dysplasia
Primary: Combined Endpoint of Bronchopulmonary Dysplasia (BPD) or Mortality — 1; 2; 24; 25 Participants
N/A N=304 The Bronchiolitis Follow-up Intervention Trial
Bronchiolitis
Primary: Parental Anxiety — 4.2; 3.9 points on a scale
Phase 2 N=27 Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
Lung Transplant Rejection · Antibody-mediated Rejection
Primary: Donor-specific HLA Antibodies, Re-transplantation, or Death — 0; 5; 3; 3 participants
N/A N=187 GER Poses a Potential Risk for Late Complications of BPD
Gastroesophageal Reflux · Bronchopulmonary Dysplasia
Primary: the Late Complications of BPD Infants — 57; 45; 30; 4 Participants
N/A N=161 Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis
Bronchiolitis · Hypoxia
Primary: Length of Stay in the Hospital — 38.7; 39.5 hours — p=<0.05
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
N/A N=320 International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation
Lung Preservation
Primary: A Composite of Patient Survival at Day 30 Post Transplantation, and Absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction…